Resources

First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes.

The first ever human data for Alogliptin, Takeda’s investigational compound for Type 2 diabetes, Alogliptin, a highly selective dipeptidyl peptidase-IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes, demonstrated efficacy in reducing glucose levels throughout the day, in an early phase clinical study.

A quick release formulation of bromocriptine mesylate in patients with type 2 diabetes improves glycemic control and reduces diabetic cardiovascular complications.

Regular self-monitoring of blood glucose, at least by people with type 2 diabetes who do not use insulin injections, did not result in a clinically significant reduction in blood glucose control in a year-long study.

Yields Insights for Developing Future “Cocktail” to Treat the Disease. Transfusion of the persons own cord blood into newly diagnosed Type 1’s, reduced the severity of their diabetes.

New Findings Likely to Lead to More Diagnoses of Gestational Diabetes. It is probable that the level of maternal blood glucose at which a diagnosis of gestational diabetes is made will soon be lowered based on the findings of this study

A major epidemiological study conducted over eight years in Australia has shown that two classes of lipid-lowering drugs – statins and fibrates – significantly lower the risk of developing nerve damage known as peripheral sensory diabetic neuropathy.

CDC statistics highlight need for improved prevention efforts.

Clinicians should not be afraid of intensifying treatment in diabetic patients with inadequately controlled glucose levels because the subsequent risk of developing hypoglycemia is quite low, a new study has shown.

People who are obese at age 18 will more likely than not develop type 2 diabetes at some point, according to a U.S. study.